Lotus Eye Hospital and Institute Ltd Stock Price Today (NSE: LOTUSEYE)
Fundamental Score
Lotus Eye Hospital and Institute Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Lotus Eye Hospital and Institute Ltd share price today is ₹124.00, up +0.00% on NSE/BSE as of 17 February 2026. Lotus Eye Hospital and Institute Ltd (LOTUSEYE) is a Small-cap company in the Hospital sector with a market capitalisation of ₹215.03 (Cr). The 52-week high for LOTUSEYE share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 320.93x, LOTUSEYE is currently trading above its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 1.22% and a debt-to-equity ratio of 0.08.
Lotus Eye Hospital and Institute Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Lotus Eye Hospital and Institute Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Lotus Eye Hospital and Institute Share Price: A Financial Analysis
The Indian healthcare sector is experiencing robust growth, fueled by an aging population and increasing healthcare awareness. This analysis examines the financial standing of Lotus Eye Hospital and Institute Ltd, focusing specifically on the "Lotus Eye Hospital and Institute share price" and related financial metrics. Currently, the share price stands at ₹122.18. A key metric to consider is the Price-to-Earnings (PE) ratio, which at 320.93, suggests that the market has very high expectations for future earnings growth. This elevated PE ratio warrants careful scrutiny, especially when considering the company's Return on Capital Employed (ROCE).
The ROCE of 2.99% is notably low. ROCE measures how efficiently a company uses its capital to generate profits. A low ROCE indicates that Lotus Eye Hospital and Institute Ltd is not generating significant returns relative to the capital it has invested. This directly impacts the company's "moat" or competitive advantage. A stronger ROCE would signify a more robust ability to fend off competition and generate sustainable profits. Comparing Lotus Eye Hospital and Institute Ltd with peers like
Nephro Care India Limited, one might delve into the qualitative aspects like management quality and strategic decision-making to understand the disparity in financial performance. Observing leadership effectiveness and strategic foresight can offer clues as to why Nephro Care India Limited is outperforming relative to the sector.The contrast in PE ratios and ROCE between Lotus Eye Hospital and Institute Ltd and its peers suggests the need for further investigation. Factors to consider include the specific services offered (e.g., specialization in a high-margin segment of eye care), the geographic footprint of the hospital network (e.g., presence in high-growth regions), and the cost structure (e.g., economies of scale in procurement). The sustainability of Lotus Eye Hospital and Institute Ltd’s earnings growth, given its current ROCE, is a key area to monitor. Further financial statement analysis is needed to get a comprehensive view of the company’s outlook.
This analysis is based on publicly available data and is intended for informational purposes only. It forms part of a larger, 80-parameter fundamental audit process that has been verified by Sweta Mishra. It is essential to conduct thorough due diligence before making any investment decisions. This is not a recommendation to buy or sell shares of Lotus Eye Hospital and Institute Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lotus Eye Hospital and Institute Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LOTUSEYE across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (20.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.08)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (1.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.99%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 320.93x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (4.09% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-12.83% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-12.83% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Lotus Eye Hospital and Institute Ltd Financial Statements
Comprehensive financial data for Lotus Eye Hospital and Institute Ltd including income statement, balance sheet and cash flow
About LOTUSEYE (Lotus Eye Hospital and Institute Ltd)
Lotus Eye Hospital and Institute Ltd (LOTUSEYE) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Hospital sector with a current market capitalisation of ₹215.03 (Cr). Lotus Eye Hospital and Institute Ltd has delivered a Return on Equity (ROE) of 1.22% and a ROCE of 2.99%. The debt-to-equity ratio stands at 0.08, reflecting the company's capital structure. Investors tracking LOTUSEYE share price can monitor key metrics including P/E ratio, promoter holding of 40.64%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
LOTUSEYE Share Price: Frequently Asked Questions
What is the current share price of Lotus Eye Hospital and Institute Ltd (LOTUSEYE)?
As of 17 Feb 2026, 10:14 am IST, Lotus Eye Hospital and Institute Ltd share price is ₹124.00. The LOTUSEYE stock has a market capitalisation of ₹215.03 (Cr) on NSE/BSE.
Is LOTUSEYE share price Overvalued or Undervalued?
LOTUSEYE share price is currently trading at a P/E ratio of 320.93x, compared to the industry average of 52.84x. Based on this relative valuation, the Lotus Eye Hospital and Institute Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of LOTUSEYE share price?
The 52-week high of LOTUSEYE share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Lotus Eye Hospital and Institute Ltd share price?
Key factors influencing LOTUSEYE share price include quarterly earnings growth (Sales Growth: 1.01%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Lotus Eye Hospital and Institute Ltd a good stock for long-term investment?
Lotus Eye Hospital and Institute Ltd shows a 5-year Profit Growth of -12.83% and an ROE of 1.22%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.08 before investing in LOTUSEYE shares.
How does Lotus Eye Hospital and Institute Ltd compare with its industry peers?
Lotus Eye Hospital and Institute Ltd competes with major peers in the Hospital. Investors should compare LOTUSEYE share price P/E of 320.93x and ROE of 1.22% against the industry averages to determine competitive standing.
What is the P/E ratio of LOTUSEYE and what does it mean?
LOTUSEYE share price has a P/E ratio of 320.93x compared to the industry average of 52.84x. Investors pay ₹321 for every ₹1 of annual earnings.
How is LOTUSEYE performing according to Bull Run's analysis?
LOTUSEYE has a Bull Run fundamental score of 22/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does LOTUSEYE belong to?
LOTUSEYE operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Lotus Eye Hospital and Institute Ltd share price.
What is Return on Equity (ROE) and why is it important for LOTUSEYE?
LOTUSEYE has an ROE of 1.22%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Lotus Eye Hospital and Institute Ltd generates profits from shareholders capital.
How is LOTUSEYE debt-to-equity ratio and what does it indicate?
LOTUSEYE has a debt-to-equity ratio of 0.08, which indicates conservative financing with low financial risk.
What is LOTUSEYE dividend yield and is it a good dividend stock?
LOTUSEYE offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Lotus Eye Hospital and Institute Ltd shares.
How has LOTUSEYE share price grown over the past 5 years?
LOTUSEYE has achieved 5-year growth rates of: Sales Growth 4.09%, Profit Growth -12.83%, and EPS Growth -12.83%.
What is the promoter holding in LOTUSEYE and why does it matter?
Promoters hold 40.64% of LOTUSEYE shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Lotus Eye Hospital and Institute Ltd.
What is LOTUSEYE market capitalisation category?
LOTUSEYE has a market capitalisation of ₹215 crores, placing it in the Small-cap category.
How volatile is LOTUSEYE stock?
LOTUSEYE has a beta of N/A. A beta > 1 suggests the Lotus Eye Hospital and Institute Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is LOTUSEYE operating profit margin trend?
LOTUSEYE has a 5-year average Operating Profit Margin (OPM) of 12.69%, indicating the company's operational efficiency.
How is LOTUSEYE quarterly performance?
Recent quarterly performance shows Lotus Eye Hospital and Institute Ltd YoY Sales Growth of 1.01% and YoY Profit Growth of 20.00%.
What is the institutional holding pattern in LOTUSEYE?
LOTUSEYE has FII holding of 0.00% and DII holding of 0.02%. Significant institutional holding often suggests professional confidence in the Lotus Eye Hospital and Institute Ltd stock.